Compare Adaptive Biotechnologies Corp (ADPT) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Exxon Mobil Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Exxon Mobil Corporation trades at $140.6 (market cap $587.30B). The key difference: Exxon Mobil Corporation is far larger — about 176.4× Adaptive Biotechnologies Corp's market cap, and Exxon Mobil Corporation pays a 2.91% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | XOM | |
|---|---|---|
Market Cap | $3.33B | $587.30B |
Sector | Health | Energy |
52-Week High | $22.37 | $171.52 |
52-Week Low | $10.24 | $105.83 |
Enterprise Value | $3.19B | $626.52B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ExxonMobil (XOM) trades at $136.44, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong operational cash flow of $52.0B in 2025 and a healthy balance sheet with 15.44% debt-to-capitalization. Recent news highlights Exxon's Permian Basin advantages and warnings about potential oil price spikes to $150-160 per barrel amid Middle East tensions.
XOM presents a mixed outlook with attractive valuation metrics (P/E 22.97, below energy sector average) and analyst consensus target of $172.79 (26% upside). However, declining revenue trends ($323.9B in 2025 vs. $398.7B in 2022) and bearish technical indicators suggest near-term headwinds. The stock offers income potential with recent $1.03 dividend but faces oil price volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
